东欧和中亚耐药结核的时空趋势分析
该研究利用WHO全球结核数据库,分析2000至2017年WHO欧洲区域18个高优先国家的结核及耐药结核通报率趋势。结果显示,近年各国新发结核通报率普遍下降,但耐药结核通报率趋势不一:2国下降、8国上升、7国稳定。提示各国对敏感结核控制优于耐药结核,耐药比例在许多地区上升。
要点
- 东欧和中亚高优先国家占区域结核发病85%和耐药结核90%以上。
- 2000-2017年多数国家新发结核通报率下降,但耐药结核趋势分化明显。
- 耐药结核通报率在8国上升、2国下降、7国稳定,耐药比例增加。
核心结论
- WHO欧洲区域国家控制敏感结核比耐药结核更成功,导致许多地区新通报患者中耐药菌株比例上升。
- 若不加强耐药结核防治,结核负担的进一步下降可能停滞。
研究设计与样本
- 计算每10万人口的新发结核及新发病例中耐药结核的年通报率,采用joinpoint回归法计算年度百分比变化并识别趋势显著变化时间点。
- 17个国家有数据(土库曼斯坦无数据)。
主要发现
- 所有17个有数据的国家在最近年份(自最后一个joinpoint以来)新发结核通报率均显著下降。
- 耐药结核通报率趋势多样,年际变异大;最近年份在爱沙尼亚和拉脱维亚下降,在阿塞拜疆、吉尔吉斯斯坦、摩尔多瓦、罗马尼亚、俄罗斯、塔吉克斯坦、乌克兰和乌兹别克斯坦上升,在亚美尼亚、白俄罗斯、保加利亚、格鲁吉亚、哈萨克斯坦、立陶宛和土耳其稳定。
临床怎么用
- 临床医生应关注来自东欧和中亚高优先国家的结核患者耐药风险,尤其来自耐药结核通报率上升国家的患者。
- 在结核诊疗中需加强耐药检测和合理治疗,以应对耐药比例上升的趋势。
局限性
- 研究基于常规监测数据,土库曼斯坦无数据,可能影响区域代表性。
- 原文未报告耐药结核通报率变化的具体数值和统计显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among all WHO regions, the WHO European Region has the highest proportion of drug-resistant tuberculosis among new and retreated cases. The 18 high-priority countries in eastern Europe and central Asia account for 85% of the tuberculosis incidence and more than 90% of drug-resistant tuberculosis cases emerging in the region. We aimed to analyse time-series trends in notification rates of drug-resistant tuberculosis among new tuberculosis cases in the 18 high-priority countries in the WHO European Region. METHODS: We used country data stored in WHO's global tuberculosis database. For each country, we calculated annual notification rates per 100 000 population of new tuberculosis cases and of drug-resistant tuberculosis among new cases reported from Jan 1, 2000, to Dec 31, 2017. We computed annual percentage changes of notification rates and identified time-points of significant change in trends using the joinpoint regression method. FINDINGS: All 17 countries with data (no data available from Turkmenistan) showed a significant decline in new tuberculosis notification rates in the most recent years since the last joinpoint if one was identified. Notification rates of drug-resistant tuberculosis showed diverse trends, with substantial year-to-year variation. In the most recent years, notification rates of drug-resistant tuberculosis among new tuberculosis cases were decreasing in two countries (Estonia and Latvia), increasing in eight countries (Azerbaijan, Kyrgyzstan, Moldova [Republic of Moldova], Romania, Russia [Russian Federation], Tajikistan, Ukraine, and Uzbekistan), and stable in seven countries (Armenia, Belarus, Bulgaria, Georgia, Kazakhstan, Lithuania, and Turkey). INTERPRETATION: Our findings suggest that countries in the WHO European Region are more successful in controlling drug-susceptible tuberculosis than drug-resistant forms, and as a result, the proportion of drug-resistant strains among newly notified patients with tuberculosis is increasing in many settings. Two countries showed that it is possible to decrease incidence of both drug-susceptible and drug-resistant tuberculosis. If no additional efforts are made in prevention and care of patients with drug-resistant tuberculosis, further decline of the tuberculosis burden will be halted. Further studies are needed to investigate the success stories and document the most effective interventions to reach the target to end tuberculosis by 2030. FUNDING: United States Agency for International Development.
引用
- Dadu A, Hovhannesyan A, Ahmedov S, et al. Drug-resistant tuberculosis in eastern Europe and central Asia: a time-series analysis of routine surveillance data. Lancet Infect Dis. 2019. PMID: 31784371. doi:10.1016/S1473-3099(19)30568-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。